Year |
Citation |
Score |
2010 |
Balliet RM, Chen G, Dellinger RW, Lazarus P. UDP-glucuronosyltransferase 1A10: activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 484-90. PMID 20007297 DOI: 10.1124/Dmd.109.030569 |
0.411 |
|
2009 |
Olson KC, Dellinger RW, Zhong Q, Sun D, Amin S, Spratt TE, Lazarus P. Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 1999-2007. PMID 19589876 DOI: 10.1124/Dmd.108.024596 |
0.389 |
|
2009 |
Balliet RM, Chen G, Gallagher CJ, Dellinger RW, Sun D, Lazarus P. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Research. 69: 2981-9. PMID 19318555 DOI: 10.1158/0008-5472.Can-08-4143 |
0.409 |
|
2008 |
Chen G, Dellinger RW, Gallagher CJ, Sun D, Lazarus P. Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenetics and Genomics. 18: 181-91. PMID 18300939 DOI: 10.1097/Fpc.0B013E3282F4Dbdd |
0.311 |
|
2008 |
Chen G, Dellinger RW, Sun D, Spratt TE, Lazarus P. Glucuronidation of tobacco-specific nitrosamines by UGT2B10. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 824-30. PMID 18238858 DOI: 10.1124/Dmd.107.019406 |
0.353 |
|
2007 |
Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, Lazarus P. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. Cancer Research. 67: 9024-9. PMID 17909004 DOI: 10.1158/0008-5472.Can-07-2245 |
0.318 |
|
2007 |
Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, Lazarus P. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 2006-14. PMID 17664247 DOI: 10.1124/Dmd.107.017145 |
0.359 |
|
2007 |
Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, Lazarus P. Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10. Carcinogenesis. 28: 2412-8. PMID 17638922 DOI: 10.1093/Carcin/Bgm164 |
0.365 |
|
2006 |
Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Research : Bcr. 8: R50. PMID 16884532 DOI: 10.1186/Bcr1539 |
0.326 |
|
2006 |
Dellinger RW, Fang JL, Chen G, Weinberg R, Lazarus P. Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 943-9. PMID 16510539 DOI: 10.1124/Dmd.105.009100 |
0.384 |
|
2003 |
Dellinger RW, Karjian PL, Neuteboom ST. NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint. Anti-Cancer Drugs. 14: 449-55. PMID 12853888 DOI: 10.1097/00001813-200307000-00011 |
0.486 |
|
2003 |
Barnes EA, Porter LA, Lenormand JL, Dellinger RW, Donoghue DJ. Human Spy1 promotes survival of mammalian cells following DNA damage. Cancer Research. 63: 3701-7. PMID 12839962 |
0.542 |
|
2002 |
Porter LA, Dellinger RW, Tynan JA, Barnes EA, Kong M, Lenormand JL, Donoghue DJ. Human Speedy: a novel cell cycle regulator that enhances proliferation through activation of Cdk2. The Journal of Cell Biology. 157: 357-66. PMID 11980914 DOI: 10.1083/Jcb.200109045 |
0.575 |
|
1999 |
Lenormand JL, Dellinger RW, Knudsen KE, Subramani S, Donoghue DJ. Speedy: a novel cell cycle regulator of the G2/M transition. The Embo Journal. 18: 1869-77. PMID 10202150 DOI: 10.1093/Emboj/18.7.1869 |
0.575 |
|
Show low-probability matches. |